Intrathecal Interferon in SSPE

Guideline-Based Treatment Recommendations

The Infectious Diseases Society of America recommends intrathecal ribavirin for SSPE with a C-III evidence grade, acknowledging that while no curative therapy exists, ribavirin is the preferred intrathecal agent 1, 2
The American College of Physicians and the Infectious Diseases Society of America implicitly support the use of intrathecal ribavirin as the primary treatment for SSPE, with interferon considered as an alternative experimental therapy based on limited evidence showing potential temporary benefit 1, 2

Interferon has significant toxicity, including profound treatment-related fatigue (90% of patients, severe in 45%), chemical meningitis (73% of patients), dose-dependent severe encephalopathy, and worse toxicity in patients who received prior cranial irradiation 3, 4, 5
Declining performance status during treatment is a common issue with interferon therapy 3, 4, 5

For newly diagnosed SSPE, the Infectious Diseases Society of America recommends considering intrathecal ribavirin as the first-line treatment (C-III recommendation) 1, 2
The use of intrathecal interferon-alpha may be considered in slowly progressive cases, particularly when ribavirin is unavailable or has failed, although it is not a guideline-recommended treatment for SSPE specifically 1, 2

The Centers for Disease Control and Prevention recommends measles vaccination as the only effective prevention strategy for SSPE, which has become increasingly rare in countries with high measles vaccination rates 6

Intrathecal ribavirin is the recommended treatment for Subacute Sclerosing Panencephalitis (SSPE), though there is no established curative therapy, according to the Infectious Diseases Society of America 7

The diagnostic workup for SSPE should include EEG, which may reveal characteristic periodic complexes with a 1:1 relationship with myoclonic jerks, as recommended by the Centers for Disease Control and Prevention 6

The Centers for Disease Control and Prevention recommends measles vaccination as the only effective prevention for SSPE, which has led to a near elimination of SSPE cases in countries with high vaccination coverage 6, 8